LARIMAR THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
LARIMAR THERAPEUTICS, INC. (LRMR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $3.48 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.48.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.95.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $5.00, a 70.65% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $2.93.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2016 was $0.75, a 61.54% decline from fiscal 2015.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2015 was $1.95, a 71.24% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.48 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $3.48 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $5.00 10-K · filed 2025-03-24 | |||
| 2024-09-30 | $5.92 10-Q · filed 2024-10-30 | |||
| 2024-06-30 | $4.69 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $2.95 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $2.93 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $2.93 10-Q · filed 2023-11-14 | |||
| 2019-09-30 | $0.75 10-Q · filed 2019-11-06 | |||
| 2016-12-31 | $0.75 10-K · filed 2017-03-10 | |||
| 2015-12-31 | $1.95 10-K · filed 2016-03-15 | |||
| 2014-12-31 | $6.78 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |